Description

10x Genomics, Inc.: How Are They Adapting to Market Conditions & Customer Needs?

10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by modest revenue growth alongside strategic advancements and evident pressures from the external economic environment. On the financial front, 10x Genomics reported a revenue increment of 4% year-over-year, reaching $153 million, driven particularly by robust demand for spatial consumables and a sequential increase in single-cell consumables. Notably, the company achieved a free cash flow positive status during the quarter. However, despite these gains, the macroeconomic environment has exerted considerable pressures, especially with regards to customer budgets affecting capital expenditure (CapEx) and thereby impacting instrument revenue. These economic challenges have compelled 10x Genomics to revise its full-year revenue guidance downwards to between $640 million and $660 million.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!